Eric Rowinsky

Biography

MD. Dr Eric Rowinsky, whose professional focus is on the optimal development and registration of anticancer therapeutics, has been a clinical consultant to Vivolux since August 2016. At this juncture, Dr Rowinsky serves as an Executive Director and President at RGenix and CFO of Clearpath Development Co. Prior to serving in these capacities, he was the Head of Research and Development, CMO, and Executive Vice President of Stemline Therapeutics. In 2010, Dr Rowinsky co-founded Primrose Therapeutics and became its CEO until it was acquired in 2011. He served as the CMO and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated. Previous to that, Eric held several positions at the Cancer Therapy & Research Center's Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Eric is a member of the board of directors of Biogen Idec. During the past five years, he has also served as a director of BIND, Navidea, and Fortress Biosciences, all of which are public life sciences companies.

Research Interest

His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.